!-- Global site tag (gtag.js) - Google Analytics -->
Select Page
June 28, 2016

CELGENE

Biotech Has Been A Barking Dog. Biotechnology promises to change the fight against major diseases, remove pain and suffering, create high paying jobs and provide prosperity for business and investors. So far many of these promises have come to pass. Even more great health benefits are in store for the future. There is, however, one big thing missing.

This content is for our beloved subscribers and anything you see on this page is just an excerpt!

Please note BullMarket.com access is available to paid subscribers only. Our Members Areas include archives of past Newsletters, News Flashes, our eight portfolios including STOCKS FOR SUCCESS, Healthcare, High Yield, High Technology, Aggressive, Real Estate Investment Trusts, Long Term Growth, and Special Opportunities. Also, all of our in-depth research is available, and more.

Already a subscriber?

Ready to join?
Subscribe Now!

June 27, 2016

CELGENE ADDED TO OPPORTUNITIES IN HEALTHCARE

June 27, 2016: Biotech Has Been A Barking Dog. Biotechnology promises to change the fight against major diseases, remove pain and suffering, create high paying jobs and provide prosperity for business and investors. So far many of these promises have come to pass. Even more great health benefits are in store for the future. There is, however, one big thing missing.

This content is for our beloved subscribers and anything you see on this page is just an excerpt!

Please note BullMarket.com access is available to paid subscribers only. Our Members Areas include archives of past Newsletters, News Flashes, our eight portfolios including STOCKS FOR SUCCESS, Healthcare, High Yield, High Technology, Aggressive, Real Estate Investment Trusts, Long Term Growth, and Special Opportunities. Also, all of our in-depth research is available, and more.

Already a subscriber?

Ready to join?
Subscribe Now!

April 7, 2016

AstraZeneca Research Report (AZN)

AstraZeneca (AZN) is a United Kingdom-based pharmaceutical firm with a solid history of delivering high quality medicines to markets globally. The company’s UK basis is also a competitive advantage in bringing drugs to market in non-FDA regions before coming stateside, a strategy few American-based firms follow.

This content is for our beloved subscribers and anything you see on this page is just an excerpt!

Please note BullMarket.com access is available to paid subscribers only. Our Members Areas include archives of past Newsletters, News Flashes, our eight portfolios including STOCKS FOR SUCCESS, Healthcare, High Yield, High Technology, Aggressive, Real Estate Investment Trusts, Long Term Growth, and Special Opportunities. Also, all of our in-depth research is available, and more.

Already a subscriber?

Ready to join?
Subscribe Now!